Chemed Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed or view top-rated stocks.

Wall Street analysts have given Chemed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chemed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chemed saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 173,600 shares, an increase of 36.6% from the June 30th total of 127,100 shares. Based on an average daily trading volume, of 89,000 shares, the short-interest ratio is presently 2.0 days. Approximately 1.1% of the company's shares are short sold.
View Chemed's Short Interest.

Chemed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) issued its quarterly earnings results on Monday, July, 26th. The company reported $4.60 earnings per share for the quarter, topping the consensus estimate of $4.29 by $0.31. The business earned $532.26 million during the quarter, compared to analysts' expectations of $511.85 million. Chemed had a trailing twelve-month return on equity of 35.40% and a net margin of 14.30%. The firm's quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the previous year, the business earned $4.41 earnings per share.
View Chemed's earnings history.

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 15.0% and is now trading at $476.07.
View which stocks have been most impacted by COVID-19.

Chemed announced a quarterly dividend on Monday, May 17th. Shareholders of record on Thursday, May 27th will be given a dividend of $0.34 per share on Wednesday, June 16th. This represents a $1.36 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Wednesday, May 26th.
View Chemed's dividend history.

Chemed pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.29%. Chemed has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 7.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.03% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

Chemed issued an update on its FY21 earnings guidance on Tuesday, July, 27th. The company provided earnings per share (EPS) guidance of $18.20-18.50 for the period, compared to the Thomson Reuters consensus estimate of $17.77.

2 brokers have issued 1-year price objectives for Chemed's shares. Their forecasts range from $580.00 to $609.00. On average, they anticipate Chemed's share price to reach $594.50 in the next year. This suggests a possible upside of 24.9% from the stock's current price.
View analysts' price targets for Chemed or view top-rated stocks among Wall Street analysts.

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), LHC Group (LHCG), R1 RCM (RCM), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of CHE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (1.07%), Fisher Asset Management LLC (0.98%), Copeland Capital Management LLC (0.63%), Trinity Street Asset Management LLP (0.28%), Alliancebernstein L.P. (0.20%) and New York State Common Retirement Fund (0.18%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Trinity Street Asset Management LLP, Fisher Asset Management LLC, New York State Common Retirement Fund, State of Michigan Retirement System, Copeland Capital Management LLC, Hanson & Doremus Investment Management, Miracle Mile Advisors LLC, and Princeton Portfolio Strategies Group LLC. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Spencer S Lee, and Thomas P Rice.
View insider buying and selling activity for Chemed or view top insider-selling stocks.

CHE stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, State of Alaska Department of Revenue, Alliancebernstein L.P., Aptus Capital Advisors LLC, Kornitzer Capital Management Inc. KS, Marshall Financial Group LLC, Capital Insight Partners LLC, and TrimTabs Asset Management LLC.
View insider buying and selling activity for Chemed or or view top insider-buying stocks.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $476.07.

Chemed has a market capitalization of $7.59 billion and generates $2.08 billion in revenue each year. The company earns $319.47 million in net income (profit) each year or $18.08 on an earnings per share basis.

Chemed employs 15,544 workers across the globe.

Chemed was founded in 1970.

The official website for Chemed is www.chemed.com.

Chemed is headquartered at 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.